If you want a Stock Review on DVAX, KERX, LJPC, or MBRX then come over to http://dailystocktracker.com/register/ …
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 22,123,456 and 18,261,557 shares issued and …
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 22,123,456 and 18,261,557 shares issued and …
ABC61mon
La Jolla Pharmaceutical Co. (NASDAQ: LJPC) has seen its shares jump on this wave with an ... in a 52-week trading range of $6.17 to $24.89. The stock has a consensus analyst price target of $36.20.
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 22,123,456 and 18,261,557 shares issued and …
La Jolla Pharmaceutical Company (NASDAQ:LJPC) yearly performance is 45.48%. The current share price …
net 2 1 1 Preferred stock dividends - (562 ) (562 ) Net loss attributable to common shareholders $ (4,284 ) $ (3,724 ) $ 560 Research and Development Expense Our research and development efforts have been focused on the development of …
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 22,123,456 and 18,261,557 shares issued and …
Following the news, La Jolla Pharmaceutical's stock price spiked 81%, trading at $36.15 per share, up $16.28, on Monday afternoon. (See also, Boston Scientific Recalls Lotus Heart Devices.) In the placebo-compared Phase 3 study of LJPC
ETFs by nature are passive index-followers, so as long as the stock remains in the index, it doesn't much matter whether analysts find the stock overvalued or undervalued. Below are some of the ETFs that hold LJPC at last report: